Proscia

Proscia is rewiring pathology for precision medicine. We’ve partnered with the world’s leading labs and biopharma companies, and are backed by $130M+ in investment to bring that mission to life.

Spaarne Gasthuis is now live on Concentriq! Yesterday, our team got the chance to visit this top clinical teaching hospital in the Netherlands to see our platform in action. In just one week, pathologists have been able to participate in multidisciplinary tumor board meetings with neighboring medical centers and read cases from home. Congratulations to the Spaarne Gasthuis team on this milestone.

Want to connect with our team at USCAP? Book a meeting here: info.proscia.com/meetings/james…

When we ask ourselves what it looks like when technology and AI actually serve pathologists, we start by listening to the labs that use it every day. That's why we're excited to have Dr. Derek Welch, President and CMO at PathGroup, join us at USCAP for a conversation about keeping expertise in pathologists' hands. March 24 · 12:00 PM · Room 1

Everyone going to USCAP has an opinion on pathology AI. We’re curious about your lab’s reality.

Grateful to be joining forces with some of our partners this year - PictorLabs, @Agilent, @awscloud, Primaa, Mindpeak, and @Barco. See you in San Antonio!

Here's what we have planned for USCAP next week: 3 days of in-booth presentations from partners working across AI, imaging, + cloud infrastructure. A Margarita Monday happy hour. And on Tuesday, a lunchtime symposium in room 1 asking a question that matters: Can Technology Make Pathology More Human? That panel features Dr. Derek Welch (PathGroup), Dr. David McClintock (Mayo Clinic), our own @davidwest_irl , and Coleman Stavish - four perspectives on where the field is heading and what the people doing the work actually need. Stop by our booth (201), grab a demo of Concentriq, and see what's new. Book a meeting with our team: info.proscia.com/meetings/james…

"Two simple, yet key, factors have helped establish my credibility as an expert clinical digital pathologist: appreciation of our team's experience and collaborative ability alongside our confidence in making informed decisions." Dr. Amanda Hemmerich of @IQVIA_global leads digital pathology strategy across five global labs - from exploratory biomarker work and AI algorithm development to clinical trial support. She's also a Concentriq user. Read her full story in @DrugTargetRev. drugtargetreview.com/article/193856…

Pharmaceutical companies depend on diagnostic partnerships but rarely have visibility into how the pathology platforms powering these laboratories actually perform at scale. The gap has real consequences for biomarker programs, trial timelines, CDx strategies, and more. For life sciences organizations, this is why our recent sweep of KLAS 2026 digital pathology ratings matters. 100% of our clinical customers surveyed by KLAS see Concentriq as part of their long-term plans, and 100% would buy again - further signaling the durability and patient reach your programs depend on. Ritida Nanda, our Senior Product Marketing Manager, takes a deeper dive in our latest blog. proscia.com/what-proscias-…

Pathology. IT. Operations. Finance. Each team evaluates platforms through a different lens, which is why alignment early in the process matters. Our Strategic Buyer’s Guide to Evaluating Digital Pathology Platforms gives selection committees a shared framework, built from hundreds of real RFPs across leading labs. The guide includes: • 200+ evaluation requirements • Security & compliance checklist • LIS integration criteria • Vendor comparison scorecards Download the guide: na2.hubs.ly/H04bsDX0

Progress in medicine is built on the work of those who came before us - and many of the discoveries that shaped modern pathology were led by women whose stories still don’t get the recognition they deserve. For Women’s History Month, our team has been sharing the stories of pioneering women in pathology in our internal conversations. We wanted to celebrate a few of them here as well. These pathologists helped transform cancer screening, infectious disease detection, and our understanding of the nervous system - and their work continues to shape the field today. Take a moment to explore the carousel, and share a story below that inspires you. #IWD

Today, 70% of Proscia customers run Concentriq on AWS, achieving implementations up to 5x faster and lowering total cost of ownership. Pathology data is massive: single slides that exceed 1.5GB, archives in the petabytes, AI workloads that demand high-performance compute. We built Concentriq on AWS to handle that reality, with secure infrastructure that scales without sacrificing performance and lets your team focus on what matters. Hear directly from our CTO Coleman Stavish and Healthcare Solutions Architect Rupesh Mishra (@awscloud) on what it means to build a purpose-built pathology platform on AWS. proscia.com/unlocking-the-…

We'll be at USCAP 2026 — and we're bringing a question worth asking. Can technology make pathology more human? During a lunch symposium on March 24th, Dr. Derek Welch (@PathGroupLabs) and Dr. David McClintock (@MayoClinic) will share what they've learned operating at scale — where technology helps, and where it falls short. They'll be joined by our own @davidwest_irl and Coleman Stavish, who will share a vision for products and workflows that keep judgment, context, and clinical responsibility in human hands. Beyond the symposium, find us at Booth #201 for demos, partner presentations, and conversations and more. Meet with us: info.proscia.com/uscap-2026?_gl…

These subtle yet impactful differences are invisible to standard PD-L1 scoring, confirming that spatial patterns provide a nuanced, personalized understanding of treatment responses that conventional biomarkers simply cannot detect. ​ Learn more and see similar research in our scientific review. 👇 proscia.com/rewiring-patho…

@nucleai_ai The AI model revealed: 🔹 Responders exhibited dense clustering of TILs in very high proximity to tumor cells. 🔹 Non-responders showed more diffuse or mixed arrangements.

While PD-L1 expression remains the most widely used biomarker for immunotherapy selection, its predictive value is often limited and inconsistent, with response rates ranging from just 13–45%.

Pathology AI that supports human expertise and helps teams work with greater clarity and efficiency is proving to be one important building block of that progress. Read the full report from the @AmericanCancer Society to learn more: cancer.org/content/dam/ca…

Five-year survival has reached 70% for patients diagnosed between 2015 and 2021, a testament to decades of progress in screening, diagnostics, and treatment. That progress happened because clinicians, researchers, and health systems invested in better tools and better processes.

More than 2.1 million people in the United States are expected to hear the words “you have cancer” in 2026. Behind each number is a person waiting for answers. A spouse refreshing a patient portal. A parent sitting in a parking lot before an appointment. A family trying to make sense of what comes next.